A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- AstraZeneca
- Study ID
- NCT06627647
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Non-squamous Non-small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rilvegostomig — DRUGAdministered as one intravenously (IV) on Day 1 of each 21-day cycle
- Pembrolizumab — DRUGAdministered as one intravenously (IV) on Day 1 of each 21-day cycle
- Carboplatin — DRUGAdministered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
- Cisplatin — DRUGAdministered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
- Pemetrexed — DRUGAdministered as one intravenously (IV) on Day 1 of each 21-day cycle
Study Details
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Key Dates
- Start date
- Nov 27, 2024
- Status verified
- May 2026
- Primary completion
- May 10, 2029
- Completion
- Mar 25, 2030
Study Design
- Enrollment
- 878 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm ARilvegostomig in combination with platinum-based doublet chemotherapy followed by rilvegostomig monotherapy plus pemetrexed in maintenance.
- Active Comparator: Arm BPembrolizumab in combination with platinum-based doublet chemotherapy followed by pembrolizumab monotherapy plus pemetrexed in maintenance.
Primary Outcome Measure
Overall survival (OS) [ Time Frame: Up to approximately 5 years ]
Central Contacts
- AstraZeneca Clinical Study Information Center1-877-240-9479
Locations (77)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | 36608 | - |
| Research Site | Chandler | Arizona | 85224 | - |
| Research Site | Phoenix | Arizona | 85054 | - |
| Research Site | Anaheim | California | 92801 | - |
| Research Site | Beverly Hills | California | 90211 | - |
| Research Site | Loma Linda | California | 92350 | - |
| Research Site | Redlands | California | 92373 | - |
| Research Site | San Diego | California | 92123 | - |
| Research Site | San Francisco | California | 94121 | - |
| Research Site | Santa Rosa | California | 95403 | - |
| Research Site | Walnut Creek | California | 94598 | - |
| Research Site | Lone Tree | Colorado | 80124 | - |
| Research Site | Stamford | Connecticut | 06902 | - |
| Research Site | West Haven | Connecticut | 06516 | - |
| Research Site | Newark | Delaware | 19713 | - |
| Research Site | Bay Pines | Florida | 33744 | - |
| Research Site | Fort Lauderdale | Florida | 33308 | - |
| Research Site | Gainesville | Florida | 32610 | - |
| Research Site | Jacksonville | Florida | 32224 | - |
| Research Site | Miami | Florida | 33125 | - |
| Research Site | Ocala | Florida | 34474 | - |
| Research Site | St. Petersburg | Florida | 33709 | - |
| Research Site | Atlanta | Georgia | 30342 | - |
| Research Site | Boise | Idaho | 83712 | - |
| Research Site | Chicago | Illinois | 60637 | - |
| Research Site | Decatur | Illinois | 62526 | - |
| Research Site | Hinsdale | Illinois | 60521 | - |
| Research Site | Quincy | Illinois | 62305 | - |
| Research Site | Rockford | Illinois | 61114 | - |
| Research Site | Waterloo | Iowa | 50702 | - |
| Research Site | Lexington | Kentucky | 40509 | - |
| Research Site | Lexington | Kentucky | 40536 | - |
| Research Site | Louisville | Kentucky | 40207 | - |
| Research Site | Alexandria | Louisiana | 71301 | - |
| Research Site | Baton Rouge | Louisiana | 70808 | - |
| Research Site | Shreveport | Louisiana | 71103 | - |
| Research Site | Shreveport | Louisiana | 71105 | - |
| Research Site | South Portland | Maine | 04106 | - |
| Research Site | Baltimore | Maryland | 21202 | - |
| Research Site | Grand Rapids | Michigan | 49503 | - |
| Research Site | Duluth | Minnesota | 55805 | - |
| Research Site | Rochester | Minnesota | 55905 | - |
| Research Site | Saint Paul | Minnesota | 55102 | - |
| Research Site | Bridgeton | Missouri | 63044 | - |
| Research Site | Columbia | Missouri | 65212 | - |
| Research Site | Lincoln | Nebraska | 68506 | - |
| Research Site | Camden | New Jersey | 08103 | - |
| Research Site | Buffalo | New York | 14221 | - |
| Research Site | Westbury | New York | 11590 | - |
| Research Site | Canton | Ohio | 44710 | - |
| Research Site | Medford | Oregon | 97504 | - |
| Research Site | Portland | Oregon | 97239 | - |
| Research Site | Salem | Oregon | 97301 | - |
| Research Site | Pittsburgh | Pennsylvania | 15212 | - |
| Research Site | York | Pennsylvania | 17403 | - |
| Research Site | Providence | Rhode Island | 02903 | - |
| Research Site | Pierre | South Dakota | 57501 | - |
| Research Site | Sioux Falls | South Dakota | 57105 | - |
| Research Site | Chattanooga | Tennessee | 37404 | - |
| Research Site | Nashville | Tennessee | 37203 | - |
| Research Site | Fort Worth | Texas | 76104 | - |
| Research Site | Houston | Texas | 77090 | - |
| Research Site | Irving | Texas | 75063 | - |
| Research Site | Kingwood | Texas | 77339 | - |
| Research Site | Lubbock | Texas | 79410 | - |
| Research Site | Palestine | Texas | 75801 | - |
| Research Site | Round Rock | Texas | 78665 | - |
| Research Site | Fairfax | Virginia | 22031 | - |
| Research Site | Norfolk | Virginia | 23502 | - |
| Research Site | Roanoke | Virginia | 24014 | - |
| Research Site | Seattle | Washington | 98101 | - |
| Research Site | Seattle | Washington | 98104 | - |
| Research Site | Silverdale | Washington | 98383 | - |
| Research Site | Spokane | Washington | 99208 | - |
| Research Site | Tacoma | Washington | 98405 | - |
| Research Site | Wenatchee | Washington | 98801 | - |
| Research Site | La Crosse | Wisconsin | 54601 | - |
Find similar trials in Mobile, AL
Related Studies
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPHASE2/PHASE3 · Recruiting · AbbVie · Chandler, Arizona